|
|
Xiaoling Xu, Shogo Kobayashi, Wenhui Qiao, Cuiling Li, Cuiying Xiao, Svetlana Radaeva, Bangyan Stiles, Rui-Hong Wang, Nobuya Ohara, Tadashi Yoshino, Derek LeRoith, Michael S. Torbenson, Gregory J. Gores, Hong Wu, Bin Gao, Chu-Xia Deng
J Clin Invest. 2006;
116(7):1843
doi:10.1172/JCI27282
Abstract |
Full text
| PDF
| Supplemental material

C
holangiocellular carcinoma (CC), the second most common primary liver cancer, is associated with a poor prognosis. It has been shown that CCs harbor alterations of a number of tumor-suppressor genes and oncogenes, yet key regulators for tumorigenesis remain unknown. Here we have generated a mouse model that develops CC with high penetrance using liver-specific targeted disruption of tumor suppressors SMAD4 and PTEN. In the absence of SMAD4 and PTEN, hyperplastic foci emerge exclusively from bile ducts of mutant mice at 2 months of age and continue to grow, leading to tumor formation in all animals at 4–7 months of age. We show that CC formation follows a multistep progression of histopathological changes that are associated with significant alterations, including increased levels of phosphorylated AKT, FOXO1, GSK-3β, mTOR, and ERK and increased nuclear levels of cyclin D1. We further demonstrate that SMAD4 and PTEN regulate each other through a novel feedback mechanism to maintain an expression balance and synergistically repress CC formation. Finally, our analysis of human CC detected PTEN inactivation in a majority of p-AKT–positive CCs, while about half also lost SMAD4 expression. These findings elucidate the relationship between SMAD4 and PTEN and extend our understanding of CC formation.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(29)
| Title and authors |
Publication |
Year |
Molecular Pathogenesis of Cholangiocarcinoma
G. Fava, I. Lorenzini
|
International Journal of Hepatology
|
2012 |
Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer
Stephen P. Malkoski, Xiao-Jing Wang
|
FEBS Letters
|
2012 |
Targeted therapy for biliary tract cancers
Jason E. Faris, Andrew X. Zhu
|
J Hepatobiliary Pancreat Sci
|
2012 |
Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma.
Min-A Seol, In-Sun Chu, Mi-Jin Lee, Goung-Ran Yu, Xiang-Dan Cui, Baik-Hwan Cho, Eun-Kyung Ahn, Sun-Hee Leem, In-Hee Kim, Dae-Ghon Kim
|
BMC Cancer
|
2011 |
Transforming Growth Factor-β in the Gastrointestinal and Hepatic Tumor Microenvironment
B.R. Achyut, Li Yang
|
Gastroenterology
|
2011 |
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression
Dongdong Lu, Chang Han, Tong Wu
|
Gastroenterology
|
2011 |
Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities
Andrew X. Zhu, Aram F. Hezel
|
Hepatology
|
2011 |
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration
Yann Malato, Syed Naqvi, Nina Schürmann, Raymond Ng, Bruce Wang, Joan Zape, Mark A. Kay, Dirk Grimm, Holger Willenbring
|
J. Clin. Invest.
|
2011 |
MicroRNAs control hepatocyte proliferation during liver regeneration.
Guisheng Song, Amar Deep Sharma, Garrett R Roll, Raymond Ng, Andrew Y Lee, Robert H Blelloch, Niels M Frandsen, Holger Willenbring
|
Hepatology
|
2010 |
The critical role of AKT2 in hepatic steatosis induced by PTEN loss.
Lina He, Xiaogang Hou, Gary Kanel, Ni Zeng, Vivian Galicia, Ying Wang, Jian Yang, Hong Wu, Morris J Birnbaum, Bangyan L Stiles
|
The American Journal of Pathology
|
2010 |
|